Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$73.52
-8.8%
$92.07
$62.70
▼
$148.83
$6.44B1.361.43 million shs14.85 million shs
Alkermes plc stock logo
ALKS
Alkermes
$44.94
-2.7%
$43.71
$27.00
▼
$55.67
$7.55B0.322.09 million shs1.07 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$50.76
-1.4%
$62.35
$50.32
▼
$88.31
$7.07B0.452.11 million shs1.43 million shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$26.14
-2.7%
$27.21
$21.52
▼
$31.97
$1.80B1.32789,090 shs738,813 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-3.76%-10.55%-12.86%-29.81%-28.57%
Alkermes plc stock logo
ALKS
Alkermes
-1.43%-1.70%+4.69%-4.45%+60.96%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+0.27%-8.37%-19.53%-33.03%-20.57%
Zymeworks Inc. stock logo
ZYME
Zymeworks
+3.15%+1.47%-0.19%-6.31%+18.85%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
$73.52
-8.8%
$92.07
$62.70
▼
$148.83
$6.44B1.361.43 million shs14.85 million shs
Alkermes plc stock logo
ALKS
Alkermes
$44.94
-2.7%
$43.71
$27.00
▼
$55.67
$7.55B0.322.09 million shs1.07 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$50.76
-1.4%
$62.35
$50.32
▼
$88.31
$7.07B0.452.11 million shs1.43 million shs
Zymeworks Inc. stock logo
ZYME
Zymeworks
$26.14
-2.7%
$27.21
$21.52
▼
$31.97
$1.80B1.32789,090 shs738,813 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-3.76%-10.55%-12.86%-29.81%-28.57%
Alkermes plc stock logo
ALKS
Alkermes
-1.43%-1.70%+4.69%-4.45%+60.96%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+0.27%-8.37%-19.53%-33.03%-20.57%
Zymeworks Inc. stock logo
ZYME
Zymeworks
+3.15%+1.47%-0.19%-6.31%+18.85%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
2.88
Moderate Buy$155.00110.82% Upside
Alkermes plc stock logo
ALKS
Alkermes
2.65
Moderate Buy$55.7324.02% Upside
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.86
Moderate Buy$106.50109.82% Upside
Zymeworks Inc. stock logo
ZYME
Zymeworks
2.79
Moderate Buy$43.2565.46% Upside

Current Analyst Ratings Breakdown

Latest ZYME, ABVX, CYTK, and ALKS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Lower Price TargetOverweight$103.00 ➝ $100.00
11/18/2026
Alkermes plc stock logo
ALKS
Alkermes
DowngradeHold (C) ➝ Hold (C-)
11/13/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Boost Price TargetMarket Outperform$32.00 ➝ $39.00
11/11/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Boost Price TargetBuy$39.00 ➝ $44.00
11/10/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Boost Price TargetBuy$34.00 ➝ $39.00
11/10/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Boost Price TargetBuy$35.00 ➝ $36.00
11/10/2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
Boost Price TargetBuy$55.00 ➝ $56.00
11/5/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Boost Price TargetBuy$99.00 ➝ $105.00
11/5/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Lower Price TargetOutperform$103.00 ➝ $100.00
11/4/2026
Alkermes plc stock logo
ALKS
Alkermes
Reiterated RatingHold (C)
11/4/2026
Alkermes plc stock logo
ALKS
Alkermes
Boost Price TargetOverweight$65.00 ➝ $68.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/A$6.57 per shareN/A
Alkermes plc stock logo
ALKS
Alkermes
$1.48B5.12$1.61 per share27.98$11.10 per share4.05
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$88.04M80.31N/AN/A($2.31) per share-21.97
Zymeworks Inc. stock logo
ZYME
Zymeworks
$105.96M17.03N/AN/A$3.74 per share6.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$380.27M-$6.06N/AN/AN/AN/A-91.69%-71.96%12/21/2026 (Estimated)
Alkermes plc stock logo
ALKS
Alkermes
$241.66M-$0.02N/A124.83N/A-0.02%0.40%0.19%N/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$784.96M-$6.04N/AN/AN/A-686.63%N/A-48.26%N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
-$81.13M$0.5250.2796.81N/A16.10%22.23%7.14%N/A

Latest ZYME, ABVX, CYTK, and ALKS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Zymeworks Inc. stock logo
ZYME
Zymeworks
$2.27$2.28+$0.01$2.28$227.40 million$512.92 million
11/4/2026Q3 2026
Alkermes plc stock logo
ALKS
Alkermes
-$0.0818$0.09+$0.1718$0.09$463.48 million$480.13 million
11/4/2026Q3 2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.43-$1.37+$0.06-$1.37$41.88 million$47.56 million
9/21/2026Q2 2026
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
-$0.9170-$1.71-$0.7930-$1.68$0.80 million$1.37 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/AN/AN/AN/AN/A
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
5.97
5.97
Alkermes plc stock logo
ALKS
Alkermes
0.79
2.42
2.02
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
3.36
3.36
Zymeworks Inc. stock logo
ZYME
Zymeworks
N/A
3.30
3.30

Institutional Ownership

CompanyInstitutional Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
47.91%
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Zymeworks Inc. stock logo
ZYME
Zymeworks
92.89%

Insider Ownership

CompanyInsider Ownership
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
N/A
Alkermes plc stock logo
ALKS
Alkermes
4.59%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.60%
Zymeworks Inc. stock logo
ZYME
Zymeworks
37.73%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abivax SA Sponsored ADR stock logo
ABVX
Abivax
9887.55 millionN/AOptionable
Alkermes plc stock logo
ALKS
Alkermes
2,050168.04 million160.33 millionOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
673139.30 million135.68 millionOptionable
Zymeworks Inc. stock logo
ZYME
Zymeworks
26469.03 million42.99 millionOptionable

Recent News About These Companies

Zymeworks (NASDAQ:ZYME) Shares Up 4.9% - What's Next?
Zymeworks Announces Participation in Upcoming Investor Conferences
Insider Selling: Zymeworks (NASDAQ:ZYME) Insider Sells $1,036,047.87 in Stock
Zymeworks (NASDAQ:ZYME) Shares Gap Up After Analyst Upgrade
Zymeworks (NASDAQ:ZYME) Board of Directors Approves Stock Repurchase Plan
Zymeworks (NASDAQ:ZYME) to Buy Back $200 million in Stock
Zymeworks Inc. authorizes a Buyback Plan.
Zymeworks (NASDAQ:ZYME) Shares Gap Up on Analyst Upgrade
Zymeworks (NASDAQ:ZYME) Price Target Raised to $44.00
HC Wainwright Reduces Earnings Estimates for Zymeworks
Citi Sticks to Its Buy Rating for Zymeworks (ZYME)
Zymeworks (NASDAQ:ZYME) Price Target Raised to $39.00

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abivax stock logo

Abivax NASDAQ:ABVX

$73.52 -7.13 (-8.84%)
Closing price 03:58 PM Eastern
Extended Trading
$74.49 +0.97 (+1.32%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Alkermes stock logo

Alkermes NASDAQ:ALKS

$44.94 -1.24 (-2.69%)
Closing price 04:00 PM Eastern
Extended Trading
$44.95 +0.01 (+0.02%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$50.76 -0.70 (-1.36%)
Closing price 03:59 PM Eastern
Extended Trading
$51.54 +0.79 (+1.55%)
As of 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Zymeworks stock logo

Zymeworks NASDAQ:ZYME

$26.14 -0.72 (-2.68%)
Closing price 04:00 PM Eastern
Extended Trading
$26.16 +0.02 (+0.06%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.